Health Catalyst(US:HCAT)2026-03-12 22:02Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, representing a 1% year-over-year growth [16][17] - In Q4 2025, total revenue was $74.7 million, down from $79.6 million in the prior year period [16][17] - Adjusted gross margin for Q4 was 53.5%, compared to 46.6% in the prior year [18] - Adjusted operating expenses for Q4 were $26.2 million, representing 35% of revenue, down from 37% in Q4 2024 [18][19] - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, leading to a GAAP net loss of $178 million, up from a loss of $69.5 million in 2024 [19][20] Business Line Data and Key Metrics Changes - Technology revenue for Q4 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services attributed to reduced FTE service offerings [17] - For the full year, technology revenue increased by 7% year-over-year to $208.3 million, while professional services revenue declined by 8% [17] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [16] - The dollar-based retention rate for technology plus TAMS closed the year at 93% [16] Company Strategy and Development Direction - The company is focused on long-term success and is conducting a strategic review to position itself better for shareholder value [6][29] - There is a renewed emphasis on simplifying the commercial engine to drive technology ARR bookings and improve retention through predictable migrations [12][13] - The company aims to leverage its intellectual property and expertise in AI to differentiate itself in the market [12] Management's Comments on Operating Environment and Future Outlook - Management noted that the healthcare market is under pressure, with clients needing to manage costs while maintaining clinical quality [40] - The company is not providing full-year guidance for 2026 but expects Q1 revenue to be between $68 million and $70 million, with Adjusted EBITDA of $7 million to $8 million [21][22] - There are anticipated challenges related to the DOS to Ignite migration, with expected revenue declines due to downselling and churn [22][23] Other Important Information - The company is undergoing leadership changes, with a new CEO emphasizing a back-to-basics approach and a focus on core capabilities [6][9] - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [9][12] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, but is currently in an assessment mode [29][31] Question: Can you elaborate on the transition impact regarding the $52 million in data platform revenue? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter facing the highest pressure during the migration [35][66] Question: What insights were gained regarding bookings and demand in Q4? - The market is in need of better cost management and clinical quality, which is reflected in the sales funnel and demand for the company's solutions [40] Question: How does the company plan to maintain client relationships amid potential downsells? - The company generally retains application relationships even when facing downsells in data platform infrastructure, focusing on client needs and expertise [49][66] Question: What is the expected impact of the DOS-related ARR churn on 2026? - Approximately 75% of the $12.5 million in ARR churn is expected to impact 2026, with negotiations ongoing to retain application relationships [65][66]